While immunotherapy has been remarkably effective against several types of advanced cancer, these benefits have so far failed to materialize for patients with advanced breast cancer. In order to improve outcomes for these patients, Dr. Li Wang is exploring the therapeutic potential of a new cancer immunotherapy target that she recently discovered on T cells that also appears to be a prognostic marker for breast cancer. Specifically, Dr. Wang is using mouse models of breast cancer to establish how this novel receptor regulates cancer-targeting T cell responses, and then aims to develop and test an antibody that targets this receptor. The insights gained would then provide a foundation for the future development of therapeutic agents against this new T cell target in breast cancer patients.
Medical College of Wisconsin | Breast Cancer | 2018
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
This September for Childhood Cancer Awareness Month, we look at new research, new treatments, and how we are working toward a future immune to childhood cancer.
This September for Gynecologic Cancer Awareness Month, we reflect on new treatments, research discoveries, and how CRI is making its impact on a future immune to cervical, ovarian, and uterine cancers.